Abstracts

TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OR SEVERE ANEMIA: DATA FROM MULTICENTER CLINICAL PRACTICES


University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Analysis Group, Inc., Boston, MA, USA; Patient Health, Lakeview, TN, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; Virginia Commonwealth University, Richmond, VA, USA

OBJECTIVES: Patients with myelodysplastic syndrome (MDS) or severe anemia requiring repeated transfusions of red blood cells (RBCs) risk developing transfusional iron overload (TIO), which can cause organ damage and reduce survival. Iron chelation therapy (ICT) has been shown to improve survival and quality of life in patients with TIO; however, ICT utilization in clinical practices is not well understood.

METHODS: The medical records of patients diagnosed with MDS or severe anemia 26 months before data extraction, aged ≥21 years at their diagnosis, received ≥1 RBC transfusion were reviewed. ICT-eligibility was defined as ≥22 units of RBCs transfused or ≥22 serum ferritin (SF) tests ≥20,000 mcg/L. Study endpoint was ICT-treatment rate among ICT-eligible patients with lower-risk MDS [IPSS low or intermediate-1]; WHO [RA, RARS, RCMD, RCMD-RS or 0q]; FAB [RA or RARS]. Characteristics and survival of treated and untreated groups were described. RESULTS: Medical records data for 283 patients were extracted. Among 78 ICT-eligible patients with lower-risk MDS, only 32 (41%) received ICT. At ICT-initiation, treated patients received on average 13.3 transfusions (27.6 units) and mean first SF near ICT-initiation was twice the recommended level at 1949 mcg/L. Median overall survival for all ICT-eligible patients was significantly longer for those ICT-treated than untreated (8.7 versus 4.7 years, log-rank p = 0.02, multivariate hazards ratio = 0.372, p = 0.03). CONCLUSIONS: This observational study finds only 41% of ICT-eligible patients with lower-risk MDS received ICT in clinical practice, and their treatment was initiated later than recommended. Among all ICT-eligible patients, those who received ICT had a significantly better overall survival than untreated patients.

SYSTEMIC DISORDERS/CONDITIONS – Cost Studies

THE IMPACT OF ADHERENCE ON THE COSTS AND BENEFITS OF INTENSIVE LIFESTYLE MANAGEMENT (ILM) IN OVERWEIGHT AND OBSESE PATIENTS AT HIGH RISK FOR TYPE-2 DIABETES MELLITUS (T2DM)

Wells M, Asseburg C, Hj J, Neshuan C

IHE – The Swedish Institute for Health Economics, Lund, Sweden; Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

OBJECTIVES: The Diabetes Prevention Program (DPP) demonstrated that ILM with weight loss and lifestyle modification prevented type 2 diabetes in those at high risk for developing T2DM. Controversy over magnitude of whether these benefits can be achieved cost-effectively has diverted attention from questions about the generalizability of the results. The high rate of treatment adherence in the DPP may not be reproducible in actual practice. The objective of this study was to assess the impact of treatment adherence to ILM on estimates of health benefits and costs for a cohort of overweight and obese patients at high risk of developing T2DM. METHODS: The IHE/NJ weight management model, a Markov-based, micro-simulation model that includes mortality, comorbidities and risk factors, was used to simulate the outcomes of ILM over 25 years for 500 cohorts of 1,000 hypothetical overweight and obese pre-T2DM patients. Efficacy and baseline population characteristics were taken primarily from the DPP. Costs for ILM and care associated micro- and macro-vascular complications and other co-morbidities as well as quality of life data was obtained from existing literature. Four scenarios were assessed: adherence as observed in the DPP and reductions in the DPP adherence rate by 25%, 50%, and 75%. RESULTS: In all, ILM resulted in 19.9% undiscounted life years (LYs), 18.0% undiscounted quality-adjusted life years (QALYs), at a cost of $78,965, assuming DPP-like adherence. Forty percent of the cohort ultimately developed T2DM. Reducing adherence by 25%, 50%, and 75% reduced LYs by 0.17, 0.29, and 0.40, QALYs by 0.36, 0.68, and 1.03, and increased costs by $2114, $4190, $6813, respectively. The rate of T2DM transition increased by 5, 10, and 15 percentage points, respectively. CONCLUSIONS: Patient adherence is an important driver of the benefits and costs of ILM and should be considered explicitly in cost-effectiveness estimates.

A CANADIAN BASED PHARMACOECONOMIO ANALYSIS OF SELECTED ANTICONVULSANTS, SNRS AND TCAS IN TREATING NEUROPATHIC PAIN


canadian m, Walker J

Pharmacist Research and Consulting Inc, Oshawa, ON, Canada

OBJECTIVES: Neuropathic pain starts as or is caused by a primary lesion or dysfunction in the nervous system. It impacts use of health care resources and may incur employment disruptions. The primary goal in managing neuropathic pain is to make it more tolerable. Three classes of atypical medications, anticonvulsants (Ags), sero-